Jupiter Life Line Hospitals Limited
Jupiter Life Line Hospitals Limited (JLHL) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
jupiterhospital.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-03
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 263 Cr | 273 Cr | 290 Cr | 287 Cr | 323 Cr | 321 Cr | 327 Cr | 348 Cr | 394 Cr | 365 Cr | 388 Cr | 411 Cr |
| Operating expenses (approx.) | 202 Cr | 211 Cr | 228 Cr | 223 Cr | 248 Cr | 246 Cr | 248 Cr | 270 Cr | 301 Cr | 282 Cr | 299 Cr | 332 Cr |
| EBITDA | 61 Cr | 62 Cr | 62 Cr | 64 Cr | 75 Cr | 75 Cr | 78 Cr | 78 Cr | 92 Cr | 83 Cr | 89 Cr | 79 Cr |
| OPM % | 23.2% | 22.7% | 21.4% | 22.2% | 23.2% | 23.4% | 24.0% | 22.5% | 23.4% | 22.8% | 23.0% | 19.3% |
| Other income | 4 Cr | 8 Cr | 9 Cr | 8 Cr | 9 Cr | 8 Cr | 7 Cr | 13 Cr | 11 Cr | 9 Cr | 9 Cr | 11 Cr |
| Interest | 12 Cr | 1 Cr | 0.93 Cr | 1 Cr | 1 Cr | 3 Cr | 6 Cr | 8 Cr | 8 Cr | 8 Cr | 9 Cr | 13 Cr |
| Depreciation | 11 Cr | 11 Cr | 10 Cr | 11 Cr | 14 Cr | 14 Cr | 18 Cr | 21 Cr | 21 Cr | 22 Cr | 23 Cr | 26 Cr |
| Profit before tax | 41 Cr | 58 Cr | 62 Cr | 60 Cr | 69 Cr | 67 Cr | 62 Cr | 62 Cr | 74 Cr | 57 Cr | 66 Cr | 51 Cr |
| Tax % | 18.6% | 24.8% | 27.2% | 25.8% | 25.3% | 21.1% | 27.7% | 28.7% | 22.6% | 25.3% | 26.2% | 25.8% |
| Net profit | 34 Cr | 44 Cr | 45 Cr | 45 Cr | 52 Cr | 53 Cr | 45 Cr | 44 Cr | 57 Cr | 42 Cr | 49 Cr | 38 Cr |
| EPS (₹) | ₹5.67 | ₹6.56 | ₹6.49 | ₹6.80 | ₹7.86 | ₹8.01 | ₹6.84 | ₹6.69 | ₹8.75 | ₹6.49 | ₹7.66 | ₹5.72 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|
| Sales | 1,070 Cr | 1,262 Cr | 1,500 Cr | Sign in for TTM |
| Operating expenses (approx.) | 831 Cr | 965 Cr | 1,157 Cr | Sign in for TTM |
| EBITDA | 238 Cr | 297 Cr | 343 Cr | Sign in for TTM |
| OPM % | 22.3% | 23.5% | 22.9% | Sign in for TTM |
| Other income | 26 Cr | 29 Cr | 42 Cr | Sign in for TTM |
| Interest | 26 Cr | 11 Cr | 33 Cr | Sign in for TTM |
| Depreciation | 42 Cr | 57 Cr | 88 Cr | Sign in for TTM |
| Profit before tax | 195 Cr | 258 Cr | 265 Cr | Sign in for TTM |
| Tax % | 9.6% | 24.9% | 25.0% | Sign in for TTM |
| Net profit | 177 Cr | 194 Cr | 199 Cr | Sign in for TTM |
| EPS (₹) | ₹28.65 | ₹29.47 | ₹29.59 | Sign in for TTM |
| Dividend payout % | 3.2% | 3.4% | 3.3% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Equity capital | 66 Cr | 66 Cr | 66 Cr |
| Reserves | 1,103 Cr | 1,291 Cr | 1,479 Cr |
| Borrowings | — | 326 Cr | 509 Cr |
| Other liabilities | 113 Cr | 223 Cr | 331 Cr |
| Total liabilities | 1,281 Cr | 1,905 Cr | 2,383 Cr |
| Fixed assets (net) | 716 Cr | 973 Cr | 1,376 Cr |
| CWIP | 74 Cr | 185 Cr | 129 Cr |
| Investments | 17 Cr | 114 Cr | 486 Cr |
| Loans & advances | 0.55 Cr | 0 Cr | 0 Cr |
| Inventories | 21 Cr | 24 Cr | 38 Cr |
| Trade receivables | 57 Cr | 42 Cr | 76 Cr |
| Cash & bank | 301 Cr | 368 Cr | 55 Cr |
| Other assets | 94 Cr | 198 Cr | 224 Cr |
| Total assets | 1,281 Cr | 1,905 Cr | 2,383 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Cash from operating activity | 115 Cr | 253 Cr | 268 Cr |
| Cash from investing | -76 Cr | -209 Cr | -442 Cr |
| Cash from financing | 128 Cr | 301 Cr | 136 Cr |
| Net cash flow | 167 Cr | 345 Cr | -38 Cr |
| Free cash flow (OCF − Capex) | 29 Cr | -67 Cr | -234 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| ROCE % | 19.0% | 15.9% | 14.5% |
| ROE % | 0.0% | 14.2% | 12.6% |
| Debtor days | 20 | 12 | 18 |
| Inventory days | 7 | 7 | 9 |
| Days payable | 21 | 30 | 23 |
| Cash conversion cycle | 6 | -11 | 4 |
| Debt / equity | — | 0.24 | 0.33 |
| Current ratio | 3.87 | 4.51 | 3.02 |
| Net debt / EBITDA | -1.26 | -0.14 | 1.32 |